The Chinese Military's BPC-157 Research Program

BPC-157 Research

3 landmark studies

A Chinese military research team at the Fourth Military Medical University independently generated the first preclinical safety profile and pharmacokinetic data for BPC-157, filling gaps the Croatian lab never addressed.

Xu et al., Regulatory Toxicology and Pharmacology, 2020; He et al., Frontiers in Pharmacology, 2022

Xu et al., Regulatory Toxicology and Pharmacology, 2020; He et al., Frontiers in Pharmacology, 2022

View as image

Nearly every BPC-157 study ever published traces back to one laboratory: Predrag Sikiric's group at the University of Zagreb in Croatia. Out of roughly 200 studies listed on PubMed, the overwhelming majority include either Sikiric or his longtime collaborator Sven Seiwerth as a named author. This concentration of research in a single group is one of the most common criticisms of the BPC-157 evidence base, and it is a legitimate concern. For the full picture of BPC-157's evidence landscape, see our pillar article.

Beginning in 2015, a research program at China's Fourth Military Medical University (FMMU) in Xi'an, now called the Air Force Medical University, began publishing BPC-157 studies that were entirely independent of the Zagreb group. These studies were conducted under the Animal Experiment Administration Committee of FMMU and funded by Chinese scientific foundations including the National Natural Science Foundation of China. They addressed three areas the Croatian lab had never systematically covered: wound healing mechanisms via specific molecular pathways, formal preclinical toxicology across four species, and the first-ever pharmacokinetic characterization of BPC-157.

Why Independent Replication Matters for BPC-157

The BPC-157 literature has a structural problem that no amount of additional Zagreb studies can fix. When one laboratory generates the vast majority of evidence for a compound, the normal self-correcting mechanisms of science do not function. Replication by independent groups with different equipment, protocols, and institutional review is what separates a promising lead from a validated finding.

The Croatian group's publications are extensive. Seiwerth and colleagues reviewed the wound healing evidence in 2021, cataloging BPC-157's effects across skin, tendon, ligament, muscle, bone, nerve, cornea, and blood vessels, noting that no toxicity has been reported and that LD1 (the dose lethal to 1% of test subjects) could not be achieved.^[5] But this review, like most BPC-157 papers, cites almost exclusively the group's own prior work.

This is where the Chinese military studies become important. They are not collaborative extensions of the Zagreb program. They use different animal models, different endpoints, different analytical methods, and different molecular targets. Their value lies not in being larger or better than the Croatian studies, but in being genuinely independent.

The 2015 Alkali-Burn Study: Wound Healing Through ERK1/2

The first FMMU publication on BPC-157, led by Huang and colleagues in 2015, used an alkali burn rat model to test topical BPC-157 treatment on chemical wound healing.^[1] Alkali burns penetrate deeper than thermal burns and are notoriously difficult to treat, making this a more demanding test than many of the wound models used in Zagreb.

The results showed that topical BPC-157 accelerated wound closure compared to controls. Histological examination on day 18 post-wounding showed better granulation tissue formation, re-epithelialization, dermal remodeling, and higher collagen deposition. BPC-157 promoted VEGF expression in wounded skin tissues and enhanced proliferation and migration of human umbilical vein endothelial cells (HUVECs) in vitro.

The mechanistic contribution was the identification of the ERK1/2 signaling pathway. BPC-157 regulated phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and its downstream targets c-Fos, c-Jun, and Egr-1, molecules involved in cell growth, migration, and angiogenesis. This provided a specific molecular explanation for wound healing effects that the Croatian studies had described in broader pharmacological terms.

For context on how this connects to BPC-157's angiogenic properties more broadly, see How BPC-157 Promotes Angiogenesis: New Blood Vessel Formation.

The 2020 Toxicology Study: Four Species, No Serious Toxicity

The most consequential Chinese military BPC-157 study was Xu and colleagues' 2020 preclinical safety evaluation, conducted at the Eye Institute of Chinese PLA, Xijing Hospital, part of FMMU.^[2] This was the first formal, multi-species toxicology assessment of BPC-157 ever published.

The study included:

• Single-dose toxicity in mice and rats: No test-related effects attributable to BPC-157 at any dose
• Repeated-dose toxicity in dogs: BPC-157 was well tolerated, with no abnormal changes between treated and control groups, except a decrease in creatinine at 2 mg/kg (not at lower doses) that resolved spontaneously after 2 weeks of withdrawal
• Local tolerance testing: Mild irritation only
• Genetic toxicity testing: No genotoxic effects
• Embryo-fetal toxicity testing: No developmental toxicity

The creatinine finding at 2 mg/kg in dogs is worth noting. The authors attributed it to pharmacological activity rather than toxicity, suggesting BPC-157 may affect renal function at high doses. This is the kind of nuanced safety signal that the Croatian literature's repeated assertion of "no toxicity, LD1 not achieved" does not capture.

This study was published in Regulatory Toxicology and Pharmacology, a journal specifically focused on drug safety evaluation for regulatory submissions. The authors stated that "these preclinical safety data contribute to the initiation of an ongoing clinical study," suggesting the Chinese program was building toward a clinical trial application.

For more on BPC-157's safety evidence and its limitations, see BPC-157 Safety Data: What Animal Studies Tell Us (and What They Don't).

The 2022 Pharmacokinetics Study: The First PK Data Ever Published

The He 2022 study, also from the FMMU/Air Force Medical University group, filled the most glaring gap in the BPC-157 literature: nobody had ever published pharmacokinetic data for the compound.^[3] After roughly 30 years of BPC-157 research, this Chinese military group provided the first characterization of how the peptide is absorbed, distributed, metabolized, and excreted.

Key findings from rats and beagle dogs:

• Elimination half-life: Under 30 minutes after intravenous administration
• Pharmacokinetic profile: Linear across all doses tested
• Intramuscular bioavailability: 14-19% in rats, 45-51% in dogs
• Excretion: Primarily through urine and bile
• Metabolism: Rapidly broken down into small peptide fragments, then single amino acids entering normal metabolic pathways
• Tritium labeling: [3H]-labeled BPC-157 was used to track distribution, providing objective measurement rather than relying on functional endpoints alone

The 30-minute half-life is a critical piece of information. It means injectable BPC-157 is cleared from circulation very quickly, raising questions about how a single daily injection produces the sustained effects reported in wound healing studies. Either BPC-157 triggers rapid signaling cascades that persist after the peptide itself is gone, it accumulates in tissues in ways not captured by plasma measurements, or the functional effects observed in animal studies are partly attributable to repeated dosing over time. The study does not resolve this question, but it defines the parameters within which any explanation must fit.

The species difference in bioavailability (14-19% in rats vs 45-51% in dogs) also has implications. If human bioavailability is closer to the dog model, intramuscular BPC-157 would reach meaningful systemic levels. If it is closer to the rat model, most of the injected dose would not reach circulation. This uncertainty matters for anyone making claims about systemic effects from injectable BPC-157.

How the Chinese Studies Differ From Zagreb

The differences between the Chinese and Croatian BPC-157 research programs are methodological, not contradictory. Both groups report positive effects. But they approach the evidence differently.

Molecular specificity: The Zagreb group describes BPC-157's effects in terms of broad pharmacological concepts. Robert's cytoprotection, NO system modulation, and interaction with multiple growth factors. The Chinese studies isolate specific signaling pathways: ERK1/2 phosphorylation in the wound model, JAK2 signaling in the Taiwanese tendon study.^[4] This makes the Chinese findings more mechanistically testable.

Regulatory-grade protocols: The Chinese toxicology and PK studies were conducted under institutional review with explicit reference to regulatory standards (the Ministry of Health of the People's Republic of China animal experiment guidelines). The Croatian studies, while published in peer-reviewed journals, have not produced a formal toxicology package suitable for regulatory submission.

Different wound models: Zagreb has tested BPC-157 in dozens of injury and disease models, often emphasizing breadth. The FMMU studies focused narrowly on alkali burns and characterized the mechanism in depth for that specific application.

PK data: Zagreb published hundreds of studies over three decades without generating pharmacokinetic data. The Chinese group prioritized it as a prerequisite for clinical translation. This difference in priorities reflects different research goals: scientific exploration (Zagreb) versus drug development pipeline (FMMU).

Independent Validation From Taiwan

The FMMU studies are not the only non-Zagreb BPC-157 research. A team at Chang Gung University in Taiwan, with no apparent ties to Sikiric, published work showing BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts.^[4] Using cDNA microarray analysis, they identified GH receptor as one of the most abundantly upregulated genes in BPC-157-treated cells. The effect was dose- and time-dependent at both mRNA and protein levels. Adding growth hormone to BPC-157-treated fibroblasts further increased cell proliferation through JAK2 activation.

The same Taiwanese group later demonstrated that BPC-157 modulates vasomotor tone through the Src-Caveolin-1-eNOS pathway, producing concentration-dependent, endothelium-dependent vasodilation in isolated rat aorta.^[6] This provided independent confirmation that BPC-157 acts through the nitric oxide system, consistent with Zagreb's claims but through a different and more precisely characterized signaling mechanism. For more on this connection, see BPC-157 and Nitric Oxide: The Vascular Connection to Healing.

These Taiwanese studies are small but meaningful. They confirm that BPC-157's cellular effects are reproducible outside the Zagreb laboratory, using different cell types, different endpoints, and different analytical techniques.

What the Chinese Program Does Not Resolve

The Chinese military studies address the independence problem and the safety data gap. They do not resolve the fundamental limitation of BPC-157 research: the absence of controlled human clinical trials.

The Xu 2020 toxicology study mentioned that the safety data would "contribute to the initiation of an ongoing clinical study." As of March 2026, no published results from a Chinese clinical trial of BPC-157 have appeared. The Zagreb group's own human trials, if they exist beyond the two brief mentions in their publications, have not produced peer-reviewed results. The missing Phase II trial for ulcerative colitis remains one of the most puzzling gaps in the BPC-157 story.

The PK data, while valuable, raises as many questions as it answers. A 30-minute half-life is extremely short for a peptide claimed to produce multi-day healing effects. Either the mechanism involves rapid trigger events that cascade independently of the peptide's presence, or the tissue-level pharmacokinetics differ substantially from plasma measurements, or some combination of both. Without human PK data, extrapolation from rats and dogs remains speculative.

The safety profile, though reassuring, was tested across limited dose ranges and durations. The creatinine signal in dogs at 2 mg/kg, while likely pharmacological rather than toxic, suggests that BPC-157 at high doses is not completely inert. Long-term safety in any species has not been assessed.

For a broader look at the limits of BPC-157's evidence base and why human trials have not materialized, see our dedicated article on this question.

The Bottom Line

The Chinese military research program at FMMU produced three studies that independently validate aspects of BPC-157's wound healing effects while filling critical gaps in safety and pharmacokinetics. The 2020 toxicology study is the most comprehensive safety evaluation ever published for BPC-157. The 2022 pharmacokinetics study provides the first absorption, distribution, metabolism, and excretion data. Combined with independent Taiwanese work on molecular pathways, these studies partially address the single-lab problem that has dogged BPC-157's credibility. They do not, however, substitute for controlled human clinical trials, which remain the missing piece of the BPC-157 evidence story.

Frequently Asked Questions

Has BPC-157 been tested by anyone other than the Croatian lab?

Yes. Researchers at China's Fourth Military Medical University (now Air Force Medical University) published three major BPC-157 studies between 2015 and 2022 with no co-authorship from Sikiric's Zagreb group. A Taiwanese team at Chang Gung University also independently confirmed BPC-157's cellular effects on tendon fibroblasts and vascular tissue. These represent the most substantial independent BPC-157 research outside Croatia.

What did the Chinese military BPC-157 safety study find?

The Xu 2020 study tested BPC-157 across four species (mice, rats, rabbits, dogs) and found no lethal dose at any level tested, no genetic toxicity, and no embryo-fetal toxicity.^[2] The only notable finding was a decrease in creatinine levels in dogs at 2 mg/kg, which reversed after 2 weeks without treatment. This is the most comprehensive preclinical safety evaluation of BPC-157 published to date.

What is BPC-157's half-life?

According to the first pharmacokinetic study (He 2022), BPC-157's elimination half-life after intravenous administration is under 30 minutes in both rats and dogs.^[3] Intramuscular bioavailability was 14-19% in rats and 45-51% in dogs. The peptide is rapidly metabolized into small peptide fragments and amino acids, excreted primarily through urine and bile.

How does the Chinese BPC-157 research differ from the Croatian studies?

The Chinese studies focus on specific molecular mechanisms (ERK1/2, VEGF pathways) rather than broad pharmacological descriptions. They also generated regulatory-grade toxicology and pharmacokinetic data suitable for clinical trial applications, which the Croatian group never published in their 30+ years of research. The Chinese work is narrower in scope but deeper in mechanistic detail and translational rigor.

Is there a Chinese clinical trial for BPC-157?

The 2020 safety study stated that the data would support "an ongoing clinical study," but as of March 2026, no published results from a Chinese human clinical trial of BPC-157 have appeared. Whether such a trial is in progress, completed but unpublished, or was never initiated is unknown.

Does the Chinese research prove BPC-157 works?

It provides independent confirmation that BPC-157 accelerates wound healing in animal models and identifies specific molecular pathways involved. It also demonstrates a clean safety profile across four species. However, animal studies in rats and dogs do not prove efficacy in humans. No controlled human clinical trial of BPC-157 has been published by any research group in any country.